Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism

Sabugo, F; Liberman C.; Niedmann, JP; Soto L.; Cuchacovich M.

Abstract

SAPHO syndrome is a rare entity that compromises the skeletal system (arthritis - osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-α) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-α blockade therapy. © Clinical Rheumatology 2007.

Más información

Título según WOS: Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism
Título según SCOPUS: Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism
Título de la Revista: Clin Rheumatol.
Volumen: 27
Asunto: 4
Editorial: Springer
Fecha de publicación: 2008-01-01
Página de inicio: 533
Página final: 535
Idioma: English
DOI/URL:

10.1007/s10067-007-0767-y

Identificador: 10.1007/s10067-007-0767-y
Notas: ISI, SCOPUS